Who is eligible for clinical trial NCT05779943?

Participants must meet protocol criteria for Prostate Adenocarcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05779943 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-10-10

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer (NCT05779943)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Emory University

🩺 Plain-English Summary (8th-Grade Level)

This phase II trial evaluates Fluorine-18 radiohybrid prostate-specific membrane antigen (18F- rhPSMA)-7.3 positron emission tomography (PET)/computed tomography (CT) scans with and without furosemide for the reduction of bladder activity in patients with prostate cancer that has come back (recurrent) based on elevated levels of prostate-specific antigen (PSA) in the blood (biochemical) after prostate surgery (prostatectomy). Furosemide is a diuretic substance that increases the urine flow into the bladder, thereby decreasing the level of radioactivity within the bladder, which may help to see any abnormal areas that could be masked by the radioactivity within the bladder. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, rhPSMA ligand. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. Adding furosemide to 18F-rhPSMA 7.3 PET/CT scans may help to better detect and treat patients with biochemically recurrent prostate cancer.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (1 items).

Location: Emory University Hospital Midtown — Atlanta, Georgia

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Adenocarcinoma of the prostate, post-prostatectomy
Biochemical recurrence of prostate cancer following radical prostatectomy (RP) with or without adjuvant or salvage therapy: PSA \>= 0.2 ng/mL followed by a subsequent confirmatory PSA value \>= 0.2 ng/mL
Age over 18
Ability to provide written informed consent
Patients with standard of care creatinine =\< 1.3 mg/dL performed within 90 days prior to enrollment

Usually NOT eligible if any of the following apply:

Exclusion Criteria: \- Inability to undergo 18F-rhPSMA PET-CT, contraindications to furosemide or urinary incontinence

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (4 Sites)

Emory University Hospital Midtown — Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Emory Saint Joseph's Hospital — Atlanta, Georgia
Emory Johns Creek Hospital — Johns Creek, Georgia

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗